NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...

Novavax, Inc. (NASDAQ:NVAX ... we expect to complete database lock of a related pediatric clinical trial in the fourth ...

Novavax Inc (NVAX) reports increased product sales and a strong cash position, while revising revenue guidance and navigating ...

J.P. Morgan analyst Eric Joseph maintained a Sell rating on Novavax (NVAX – Research Report) yesterday and set a price ... which has faced delays due to a clinical hold by the FDA. Although the hold ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...

Novavax received clearance from the FDA to move forward with phase 3 clinical trials for its COVID-19-influenza combination (CIC) and standalone influenza vaccines. The FDA lifted a clinical hold that ...

Novavax, Inc. ( NASDAQ: NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET ...

Novavax's (NVAX) stock was trading down more than 6% Tuesday ... as well as restart its Phase 3 flu-COVID combination vaccine ...

Novavax does not expect a significant impact from the clinical hold and plans to start the late-stage trial as soon as ...

More doctors are looking out for the condition. But that’s not enough to explain the increase in the nation’s overall ...